Opportunity for Innovation in Relapsing Remitting Multiple Sclerosis
Read More
November 2026
The Opportunity for Innovation in Relapsing Remitting Multiple Sclerosis
A value-centric framework around the broader progress that innovation could deliver patients, caregivers, health systems, and society.
In this Center for Pharmacoeconomics Spotlight, we quantify the impact of relapsing remitting multiple sclerosis (RRMS) on patient health, caregiver time, medical costs, and workforce participation to estimate the societal value that could be created if innovation could restore outcomes among people living with RRMS to those of the general US population.
RRMS is a lifelong, progressive condition that often begins relatively early in life. By affecting mobility, cognition, and survival, RRMS can substantially reduce both the quality and length of life. This creates enormous gaps in outcomes compared with the general population.
Closing the lifetime gaps in outcomes between a person living with RRMS treated with best supportive care and a person from the general population has the potential to:
- Create $5.7-$18.7 million in value from improved health per person living with RRMS.
- Free up $654,000 worth of caregiver time per person living with RRMS.
- Avoid $347,000 in disease-related healthcare costs per person living with RRMS.
- Produce $977,000 in additional labor production per person living with RRMS.
Safe and effective treatments for RRMS can unlock substantial value for patients, caregivers, health systems, and society. The value created by a safe and effective therapeutic for RRMS can extend well beyond its market exclusivity period and these lifecycle considerations should be considered when assessing and communicating the societal value proposition for potentially novel therapeutics.
This report is not about the reimbursement or pricing of specific therapeutics but about the broader progress that innovation in RRMS could deliver for patients, caregivers, health systems, and society. Understanding the magnitude and duration of this progress can help inform whether an innovation will ultimately be “worth it” to society.
For details on obtaining full access to the report, contact us via email at cpe@medacorp.com.
The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners
Leerink Center for Pharmacoeconomics
– Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
Disclosures
The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.
© 2026 MEDACorp LLC. All Rights Reserved.
